JAGX — Jaguar Health Cashflow Statement
0.000.00%
- $2.01m
- $42.17m
- $11.51m
Annual cashflow statement for Jaguar Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -52.6 | -49.1 | -41.9 | -39 | -54.4 |
| Depreciation | |||||
| Non-Cash Items | 13.6 | 18.4 | 17.7 | 10.8 | 12.3 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.27 | -4.43 | -11.1 | -3.01 | 16.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -35 | -33.1 | -33.2 | -29.4 | -23.7 |
| Capital Expenditures | -0.006 | -1.68 | 0 | -0.231 | -0.041 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -0.006 | -1.68 | 0 | -0.231 | -0.041 |
| Financing Cash Flow Items | -0.731 | -1.16 | 0.38 | -0.1 | -0.05 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 43.9 | 23.2 | 34.2 | 31.2 | 23.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 8.96 | -11.6 | 1 | 1.53 | -0.17 |